The ARHGAP11A Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated by targeted disruption of the ARHGAP11A gene in the HeLa cell line. This product delivers a heterogeneous pool of cells carrying diverse gene-editing events, providing a loss-of-function model without clonal isolation and minimizing the risk of clonal artifacts. The polyclonal format enables rapid experimental deployment for investigating ARHGAP11A biology in a cancer-relevant background.
The host HeLa cell line is an immortalized human cervical carcinoma line widely employed as a model system in cancer research. HeLa cells are characterized by robust proliferation, straightforward culture conditions, and thoroughly documented signaling pathways, making them a standard platform for studying oncogenic processes, cell cycle control, and cytoskeletal dynamics.
ARHGAP11A encodes a Rho GTPase-activating protein (RhoGAP) that stimulates GTP hydrolysis on Rho family GTPases such as RhoA, Rac1, and Cdc42, converting them to an inactive GDP-bound state. This inactivation serves as a key regulatory node in actin cytoskeleton reorganization and cell cycle progression. ARHGAP11A expression is controlled by E2F transcription factors and mitogenic signals, and its activity modulates the RhoA?CRock?CLIMK?Ccofilin axis, directly impacting actin dynamics. ARHGAP11A interacts with Rho GTPases, G-actin, and F-actin, positioning it at the intersection of growth factor signaling and cytoskeletal remodeling.
In the HeLa cervical carcinoma context, ARHGAP11A disruption may impair cytokinesis and alter proliferation, modeling the consequences of RhoGAP dysfunction in malignant cells. This knockout system enables dissection of how aberrant actin regulation contributes to division defects and the cytoskeletal abnormalities observed in cancer, offering a path to examine Rho GTPase-driven mechanisms in tumor cell biology.
This polyclonal knockout cell population is suited for a broad range of experimental applications, including cell cycle analysis by flow cytometry, Rho GTPase activity assays, western blotting, and immunofluorescence for actin architecture visualization. Functional studies such as proliferation, migration, and invasion assays can be performed to assess ARHGAP11A??s role in cancer cell behavior, and the cells are amenable to Hippo pathway investigations given the cross-talk between Rho GTPases and YAP/TAZ regulation. For further information and technical support, please contact Ascent Research.
